nach oben

Tumor Biology

Erschienen in:

01.05.2015 | Research Article

Diagnostic value of [¹⁸F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis

verfasst von: Huojun Zhang, Wei Xing, Qinqin Kang, Chao Chen, Linhui Wang, Jianping Lu

Erschienen in: Tumor Biology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

An early diagnosis of urinary bladder cancer is crucial for early treatment and management. The objective of this systematic review was to assess the overall diagnostic accuracy of 18 F FDG-PET and PET/CT in urinary bladder cancer with meta-analysis. The PubMed and CNKI databases were searched for the eligible studies published up to June 01, 2014. The sensitivity, specificity, and other measures of accuracy of 18 F FDG-PET and PET/CT in the diagnosis of urinary bladder cancer were pooled along with 95 % confidence intervals (CI). Summary receiver operating characteristic (ROC) curves were used to summarize overall test performance. Ten studies met our inclusion criteria. The summary estimates for 18 F FDG-PET and PET/CT in the diagnosis of urinary bladder cancer in meta-analysis were as follows: a pooled sensitivity, 0.82 (95 % confidence interval [CI], 0.75 to 0.88); a pooled specificity, 0.92 (95 % CI, 0.87 to 0.95); positive likelihood ratio, 6.80 (95 % CI, 4.31 to 10.74); negative likelihood ratio, 0.27 (95 % CI, 0.19 to 0.36); and diagnostic odds ratio, 25.18 (95 % CI, 17.58 to 70.4). The results indicate that 18 F FDG-PET and PET/CT are relatively high sensitive and specific for the diagnosis of urinary bladder cancer.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.CrossRefPubMed

Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163(6):1693–6.CrossRefPubMed

Voges GE, Tauschke E, Stöckle M, Alken P, Hohenfellner R. Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol. 1989;142(4):972–4.PubMed

Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38:70–86.CrossRefPubMedPubMedCentral

Chiti A, Picchio M. The rising PET: the increasing use of choline PET/CT in prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38:53–4.CrossRefPubMed

Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188–93.CrossRefPubMed

Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22(21):4357–68.CrossRefPubMed

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44(8):1200–9.PubMed

10.

Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET andPET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44(11):1797–803.PubMed

11.

Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for reporting of diagnostic accuracy: towards complete and accurate reporting of studies of diagnostic accuracy; the STARD initiative. BMJ. 2003;326:41–4.CrossRefPubMedPubMedCentral

12.

Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.CrossRefPubMedPubMedCentral

13.

Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.CrossRefPubMedPubMedCentral

14.

Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.CrossRefPubMed

15.

Lau J, Ioannidis JP, Balk EM, et al. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. Ann Emerg Med. 2001;37:453–60.CrossRefPubMed

16.

Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–76.CrossRefPubMed

17.

Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med. 1998;122:675–86.PubMed

18.

Suzuki S, Moro-oka T, Choudhry NK. The conditional relative odds ratio provided less biased results for comparing diagnostic test accuracy in meta-analyses. J Clin Epidemiol. 2004;57:461–9.CrossRefPubMed

19.

Westwood ME, Whiting PF, Kleijnen J. How does study quality affect the results of a diagnostic meta-analysis? BMC Med Res Methodol. 2005;8:20.CrossRef

20.

Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentral

21.

Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32(12):1412–7.CrossRefPubMed

22.

Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C. Camargo EE.18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48(5):764–70.CrossRefPubMed

23.

Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13(1):42–7.CrossRefPubMedPubMedCentral

24.

Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27(26):4314–20.CrossRefPubMedPubMedCentral

25.

Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging. 2010;20(1):13–9.CrossRefPubMedPubMedCentral

26.

Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28(25):3973–8.CrossRefPubMedPubMedCentral

27.

Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, et al. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol. 2011;45(2):122–8.CrossRefPubMed

28.

Yang Z, Cheng J, Pan L, Hu S, Xu J, Zhang Y, et al. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer? Ann Nucl Med. 2012;26(7):571–7.CrossRefPubMed

29.

Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2013. doi:10.1111/bju.12608.

30.

Nayak B, Dogra PN, Naswa N, Kumar R. Diuretic 18 F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging. 2013;40(3):386–93.CrossRefPubMed

31.

Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007;244:39–47.CrossRefPubMed

32.

Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118.CrossRefPubMed

33.

Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–92.CrossRefPubMed

34.

Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641–7.CrossRefPubMed

35.

Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81:2411–6.CrossRefPubMed

36.

Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRef

Titel: Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis
verfasst von: Huojun Zhang
Wei Xing
Qinqin Kang
Chao Chen
Linhui Wang
Jianping Lu
Publikationsdatum: 01.05.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 5/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2361-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostic value of [¹⁸F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer

The tumor suppressor role of PAQR3 in osteosarcoma

Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling

Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways

Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer

Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27kip pathway in human glioblastoma cells

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie